Abstract
Recently, there have been estimates of 390 million dengue infections annually worldwide. Thus, Dengue viruses (DENV) continue to result in a severe burden on the human health all over the world. There are four different serotypes of DENV depending on antigenicity. Each can result in a life-threatening condition. For such a severe disease, present-day options of treatment are certainly limited and most patients rely on supportive care. Although there has been a dengue vaccine approved with modest efficacy, there is an urgent need for drugs that can reduce the complications that occur as a result of dengue. Some recent advances have been made in the development of drugs for combating dengue. These include some new vaccine candidates, invention of peptide-based drugs (antimicrobial peptides or AMPs), and repurposing of a few existing ones. Out of these, peptide-based drugs are recently under the limelight for their enhanced efficacy against the DENV and are being tested for their efficacy in preventing dengue in different parts of the world. In this context, we have developed a database that highlights the efforts made in the direction of peptide-based drugs against DENV. The database mentions the important features of all the anti-DENV peptides recorded up to date. These include source, target, mode of action, sequence, length, IC50, toxicity, etc. Our database also presents a holistic view of the overall situation of the peptide-based discovery for dengue. The database is accessible via any web browser at https://bblserver.org.in/adpdb/.